Nurix Therapeutics (NRIX) Enterprise Value (2019 - 2025)
Nurix Therapeutics (NRIX) has disclosed Enterprise Value for 7 consecutive years, with -$592.9 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value rose 2.73% to -$592.9 million in Q4 2025 year-over-year; TTM through Nov 2025 was -$592.9 million, a 2.73% increase, with the full-year FY2025 number at -$592.9 million, up 2.73% from a year prior.
- Enterprise Value was -$592.9 million for Q4 2025 at Nurix Therapeutics, down from -$428.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$244.0 million in Q1 2024 to a low of -$609.6 million in Q4 2024.
- A 5-year average of -$372.4 million and a median of -$326.5 million in 2021 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: grew 24.86% in 2023, then tumbled 125.29% in 2025.
- Nurix Therapeutics' Enterprise Value stood at -$295.7 million in 2021, then fell by 4.54% to -$309.1 million in 2022, then rose by 6.87% to -$287.9 million in 2023, then tumbled by 111.73% to -$609.6 million in 2024, then grew by 2.73% to -$592.9 million in 2025.
- Per Business Quant, the three most recent readings for NRIX's Enterprise Value are -$592.9 million (Q4 2025), -$428.8 million (Q3 2025), and -$485.8 million (Q2 2025).